New heart failure drug candidate passes first safety hurdle in obese volunteers

NCT ID NCT07186946

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a single dose of the investigational drug THRV-1268 in 16 healthy obese adults to see if it is safe and tolerable. The drug is being developed as a potential treatment for heart failure. The study did not test effectiveness, only safety and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

THRV-1268

What this could lead to

If safe, this could lead to larger trials testing whether THRV-1268 helps control heart failure in people with obesity.

What could go wrong

This is a very early Phase 1 safety study with only 16 healthy people. It does not test if the drug works for heart failure, and many early drugs fail in later stages.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation heart failure Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dr. Vince Clinical Research

    Overland Park, Kansas, 66212, United States